Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone.

$ZYME insiders have traded $ZYME stock on the open market 11 times in the past 6 months. Of those trades, 6 have been purchases and 5 have been sales. Here’s a ...

So, the natural question for Zymeworks (NASDAQ:ZYME) shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual rate at ...

Jeffrey T L Smith, the EVP & Chief Medical Officer of $ZYME ($ZYME), sold 11,110 shares of the company on 01-06-2025. We received data on the trade from a recent SEC ...

The Zymeworks (NASDAQ:ZYME) story over the last two years was one of transformation and execution. The process started with the out-licensing of Ziihera, the brand name for zanidatamab ...